This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Y.
Right arrow Articles by Saiman, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Y.
Right arrow Articles by Saiman, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2005, p. 2510-2511, Vol. 49, No. 6
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.6.2510-2511.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

Yunhua Chen,1 Elizabeth Garber,1 Qiuqu Zhao,1 Yigong Ge,2 Matthew A. Wikler,2 Koné Kaniga,2 and Lisa Saiman1*

Department of Pediatrics, Columbia University, New York, New York,1 Peninsula Pharmaceuticals, Inc., Alameda, California2

Received 12 November 2004/ Returned for modification 12 January 2005/ Accepted 9 February 2005

Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa (n = 200 strains), nonmucoid P. aeruginosa (n = 200), and Burkholderia cepacia complex (n = 200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 µg/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.

* Corresponding author. Mailing address: Columbia University, 622 West 168th St., PH4W-470, New York, NY 10032. Phone: (212) 305-9446. Fax: (212) 305-9491. E-mail: LS5{at}columbia.edu.

Antimicrobial Agents and Chemotherapy, June 2005, p. 2510-2511, Vol. 49, No. 6
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.6.2510-2511.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Baughman, R. P. (2009). The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24: 230-241 [Abstract]  
  • Kim, A., Banevicius, M. A., Nicolau, D. P. (2008). In Vivo Pharmacodynamic Profiling of Doripenem against Pseudomonas aeruginosa by Simulating Human Exposures. Antimicrob. Agents Chemother. 52: 2497-2502 [Abstract] [Full Text]  
  • Credito, K. L., Ednie, L. M., Appelbaum, P. C. (2008). Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis. Antimicrob. Agents Chemother. 52: 365-373 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»